News and Insights
The latest news and insights from Genoa Healthcare.
- Behavioral Health
- Clinical Insights
- Treatment
3 Trends to follow this flu season
According to the CDC, flu season runs rampant from October through May.1 Looking to keep the people you serve safe during the 2023-2024 flu season? Keep these three trends on...
- Oct 4th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
September 2023 drug trend report
Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Brixadi™ Zurzuvae™ (zuranolone) Generic drug...
- Sep 1st, 2023
- Behavioral Health
- Clinical Insights
Caring for those with treatment-resistant depression
Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today. One in three adults with major depressive disorder...
- Aug 9th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
4 things to know about Spravato® (Intranasal esketamine)
Looking for information on Spravato®? Here are four things you should know. Spravato®: What, why and how? Spravato® is an FDA-approved nasal spray indicated for the treatment of treatment-resistant depression...
- Aug 9th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
August 2023 drug trend report
Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market. Brand name drug launches* Uzedy Abilify Asimtuffii Brixadi Generic...
- Aug 2nd, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Aug 2nd, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Frequently asked questions: naloxone (Narcan®)
Narcan® information and sources were taken from www.narcan.com. 1. FDA Approves First Over-the-Counter Naloxone Nasal Spray. 3/29/2023. FDA Approves First Over-the-Counter Naloxone Nasal Spray | FDA
- Mar 29th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Frequently asked questions: buprenorphine-containing products
Information and sources on buprenorphine-containing products were taken from www.sublocade.com and www.suboxone.com.
- Mar 6th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
What’s on the horizon: four emerging trends in the medication-assisted treatment space
1X-Waiver no longer need to treat opioid use disorder. (2023, January 13). ACEP. 2. Sublocade. 3.BMC launces app to help providers treat patients with opioid use disorder. (2021, March 22)....
- Mar 6th, 2023
- Behavioral Health
- Clinical Insights
- Treatment
Why medication-assisted treatment is essential for improving patient outcomes
1. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH. 2. Methadone and buprenorphine reduce risk of death after opioid overdose. (2018, June 19). NIH....
- Mar 6th, 2023